
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
Managed Healthcare Executive recently had a wide-ranging conversation with de Brantes about COVID-19, the healthcare sector and how the precipitous drops in utilization and provider revenue may affect the future of bundled payment and other alternative payment models.
Managed Healthcare Executive recently had a wide-ranging conversation with de Brantes about COVID-19, the healthcare sector and how the precipitous drops in utilization and provider revenue may affect the future of bundled payment and other alternative payment models.
To listen to more episodes featured on Tuning Into The C-Suite, visit us on






